Read More

Aldeyra Therapeutics Schedules Conference Call And Webcast On Tuesday, December 19, 2023, At 8:00 a.m. To Announce Top-Line Results From Phase 2 Clinical Trial Of ADX-629 In Patients With Atopic Dermatitis

Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, December 19, 2023, at 8:00 a.m. (ET) to provide top-line results from a Phase 2 clinical trial of

ALDX

Read More

Why Is Itch-Focused Cara Therapeutics Stock Trading Lower Today?

Cara Therapeutics Inc (NASDAQ: CARA) announced the outcome from the dose-finding Part A of the KIND 1 study evaluating the efficacy and safety of oral difelikefalin as adjunct therapy to topical corticosteroids (TCS) for moderate-to-severe pruritus in adult patients with 

CARA

Read More

Vera Therapeutics’ Kidney Disease Drug Has Opportunity In A Competitive Development Landscape: Analyst

Raymond James initiated coverage on Vera Therapeutics Inc (NASDAQ: VERA), a late-stage drug developer in the autoimmune kidney space. The lead asset, atacicept, is a BLyS/APRIL dual inhibitor fusion protein currently in a Phase 3 study in IgA Nephropathy (IgAN).

VERA